-
Committee for Medicinal Products for Human Use (CHMP) recommends granting marketing authorisation for FIRMAGON® (degarelix) for treatment of prostate cancer
in PRESS RELEASE 2008 onFerring Pharmaceuticals received today notification that the Committee…
-
Ferring and Conaris complete license agreement for new recombinant molecule in gastroenterology
in PRESS RELEASE 2008 onFerring Pharmaceuticals and Conaris Research Institute AG today announced that they have completed…
-
Ferring signs distribution agreement with BioGaia in Ireland and the Middle East
in PRESS RELEASE 2008 onBioGaia has extended its collaboration with the Swiss biopharmaceutical company Ferring Pharmaceuticals giving Ferring exclusive rights to sell BioGaia’s Probiotic Drops in Ireland and…
-
Auxilium Pharmaceuticals, Inc. Announces Distribution and License Agreement for Testim® in Europe with Ferring Pharmaceuticals
in PRESS RELEASE 2008 onAuxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) and Ferring International S.A. today announced…
-
Positive phase III data unveiled for new GnRH blocker degarelix
in PRESS RELEASE 2008 onData from a Phase III study presented at the 23rd Annual European Association of Urology Congress demonstrated that the investigational GnRH blocker, degarelix…
-
Ferring Pharmaceuticals submits new drug application for degarelix, a prostate cancer treatment
in PRESS RELEASE 2008 onFerring Pharmaceuticals announced today that it has submitted applications in Europe and the United States for…
-
Launch of new, prestigious infertility and gynaecology research grant (FRIGGA) at “Update in Infertility 2008”
in PRESS RELEASE 2008 onFerring Pharmaceuticals today launches the first Ferring Research Infertility and Gynaecology GrAnt (FRIGGA) for fundamental fertility and gynaecology research…
-
Ferring pharmaceuticals completes phase III study of degarelix in prostate cancer patients
in PRESS RELEASE 2007 onFerring Pharmaceuticals announced today that it has successfully completed the pivotal phase III study for degarelix, its novel prostate cancer treatment…
-
Superior remission rates for once daily use of Pentasa® (mesalazine) in ulcerative colitis
in PRESS RELEASE 2007 onFor the first time a once daily dosing regime of mesalazine (Pentasa® granules) has proven to be statistically superior to…
-
Ferring Pharmaceuticals Forges Worldwide Licensing Agreement for Budesonide MMX™
in PRESS RELEASE 2007 onFerring Pharmaceuticals today announced that it had come to an agreement with Cosmo Pharmaceuticals SpA for…
Author archive for pulse
Articles by: pulse
